...
search icon
argx-img

argenx NV ADR, Common Stock

ARGX

NSQ

$649.67

+$9.77

(1.53%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$37.54B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
49.9922
Volume info-icon
This is the total number of shares traded during the most recent trading day.
318.11K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.20
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$352.77 L
$678.21 H
$649.67

About argenx NV ADR, Common Stock

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameARGXSectorS&P500
1-Week Return5.68%-1.02%1.43%
1-Month Return11.32%-5.31%-1.07%
3-Month Return-1.2%-7.33%-6.61%
6-Month Return10.36%-6.9%-2%
1-Year Return65.13%-2.73%10.58%
3-Year Return121.47%5.53%34.71%
5-Year Return349.72%39.74%96.96%
10-Year Return2724.65%86.82%165.02%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue41.24M497.28M410.75M1.23B2.19B[{"date":"2020-12-31","value":1.88,"profit":true},{"date":"2021-12-31","value":22.7,"profit":true},{"date":"2022-12-31","value":18.75,"profit":true},{"date":"2023-12-31","value":55.99,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue303.93M510.04M29.43M117.83M227.29M[{"date":"2020-12-31","value":59.59,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":5.77,"profit":true},{"date":"2023-12-31","value":23.1,"profit":true},{"date":"2024-12-31","value":44.56,"profit":true}]
Gross Profit41.24M497.28M381.32M1.11B1.96B[{"date":"2020-12-31","value":2.1,"profit":true},{"date":"2021-12-31","value":25.33,"profit":true},{"date":"2022-12-31","value":19.43,"profit":true},{"date":"2023-12-31","value":56.47,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%92.83%90.39%89.62%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":92.83,"profit":true},{"date":"2023-12-31","value":90.39,"profit":true},{"date":"2024-12-31","value":89.62,"profit":true}]
Operating Expenses518.86M846.02M1.10B1.53B1.98B[{"date":"2020-12-31","value":26.14,"profit":true},{"date":"2021-12-31","value":42.63,"profit":true},{"date":"2022-12-31","value":55.51,"profit":true},{"date":"2023-12-31","value":77.27,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(477.62M)(348.75M)(720.34M)(425.05M)(21.65M)[{"date":"2020-12-31","value":-47761700000,"profit":false},{"date":"2021-12-31","value":-34874600000,"profit":false},{"date":"2022-12-31","value":-72034100000,"profit":false},{"date":"2023-12-31","value":-42504900000,"profit":false},{"date":"2024-12-31","value":-2165400000,"profit":false}]
Total Non-Operating Income/Expense(129.15M)(51.94M)14.79M212.61M243.11M[{"date":"2020-12-31","value":-53.12,"profit":false},{"date":"2021-12-31","value":-21.37,"profit":false},{"date":"2022-12-31","value":6.08,"profit":true},{"date":"2023-12-31","value":87.45,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(605.35M)(399.74M)(729.31M)(304.50M)85.18M[{"date":"2020-12-31","value":-710.67,"profit":false},{"date":"2021-12-31","value":-469.29,"profit":false},{"date":"2022-12-31","value":-856.2,"profit":false},{"date":"2023-12-31","value":-357.47,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes3.10M8.52M(19.72M)(9.44M)(792.56M)[{"date":"2020-12-31","value":36.41,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-231.4,"profit":false},{"date":"2023-12-31","value":-110.81,"profit":false},{"date":"2024-12-31","value":-9300.21,"profit":false}]
Income After Taxes(608.46M)(408.26M)(709.59M)(295.05M)877.74M[{"date":"2020-12-31","value":-69.32,"profit":false},{"date":"2021-12-31","value":-46.51,"profit":false},{"date":"2022-12-31","value":-80.84,"profit":false},{"date":"2023-12-31","value":-33.61,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations(528.92M)(408.26M)(709.59M)(295.05M)833.04M[{"date":"2020-12-31","value":-63.49,"profit":false},{"date":"2021-12-31","value":-49.01,"profit":false},{"date":"2022-12-31","value":-85.18,"profit":false},{"date":"2023-12-31","value":-35.42,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(608.46M)(408.26M)(709.59M)(295.05M)833.04M[{"date":"2020-12-31","value":-73.04,"profit":false},{"date":"2021-12-31","value":-49.01,"profit":false},{"date":"2022-12-31","value":-85.18,"profit":false},{"date":"2023-12-31","value":-35.42,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
EPS (Diluted)(11.65)(7.85)(13.12)(5.33)1.51[{"date":"2020-12-31","value":-770.25,"profit":false},{"date":"2021-12-31","value":-519.01,"profit":false},{"date":"2022-12-31","value":-867.44,"profit":false},{"date":"2023-12-31","value":-352.4,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ARGX
Cash Ratio 5.04
Current Ratio 7.29
Quick Ratio 6.68

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ARGX
ROA (LTM) -0.21%
ROE (LTM) 17.36%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ARGX
Debt Ratio Lower is generally better. Negative is bad. 0.11
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.89

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ARGX
Trailing PE 49.99
Forward PE 92.59
P/S (TTM) 17.47
P/B 7.11
Price/FCF 995
EV/R 16.41
EV/Ebitda 341.67
PEG NM

FAQs

What is argenx NV ADR share price today?

argenx NV ADR (ARGX) share price today is $649.67

Can Indians buy argenx NV ADR shares?

Yes, Indians can buy shares of argenx NV ADR (ARGX) on Vested. To buy argenx NV ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ARGX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of argenx NV ADR be purchased?

Yes, you can purchase fractional shares of argenx NV ADR (ARGX) via the Vested app. You can start investing in argenx NV ADR (ARGX) with a minimum investment of $1.

How to invest in argenx NV ADR shares from India?

You can invest in shares of argenx NV ADR (ARGX) via Vested in three simple steps:

  • Click on Sign Up or Invest in ARGX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in argenx NV ADR shares
What is argenx NV ADR 52-week high and low stock price?

The 52-week high price of argenx NV ADR (ARGX) is $678.21. The 52-week low price of argenx NV ADR (ARGX) is $352.77.

What is argenx NV ADR price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of argenx NV ADR (ARGX) is 49.9922

What is argenx NV ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of argenx NV ADR (ARGX) is 7.11

What is the Market Cap of argenx NV ADR?

The market capitalization of argenx NV ADR (ARGX) is $37.54B

What is argenx NV ADR’s stock symbol?

The stock symbol (or ticker) of argenx NV ADR is ARGX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top